It’s the big stage over there, obviously a lot of steps to climb and hoops to jump through, but fully funded preclinical is a huge tick and whilst RX7 is probably the main game in terms of replacement or alternative therapies for opioids it’s helpful that actual Phase 3 trials are underway for the lower threshold (over the counter) RX5.
You’d expect the larger pharma’s being forced out of the opioid business and reaching settlements worth billions will be looking for an alternative product that is proven safe, so seems the company is prepping for a big 2023.
This arm of the business is definitely the one to watch for me, they’re well placed as a smaller company to fill the spaces being left by the big pharmas still being sued for billions over their pain relief preparations.
EMD Price at posting:
19.0¢ Sentiment: Hold Disclosure: Held
